These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 23402675)
1. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Abbruzzese G; Barone P; Bonuccelli U; Lopiano L; Antonini A Funct Neurol; 2012; 27(3):147-54. PubMed ID: 23402675 [TBL] [Abstract][Full Text] [Related]
2. [Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease]. Fernandez-Pajarin G; Ares-Pensado B; Sesar A; Iglesias-Canle J; Masa-Vazquez L; Castro A Rev Neurol; 2018 Jul; 67(1):1-5. PubMed ID: 29923594 [TBL] [Abstract][Full Text] [Related]
3. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease. Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769 [TBL] [Abstract][Full Text] [Related]
16. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety]. Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100 [TBL] [Abstract][Full Text] [Related]
17. Use of advanced therapies for Parkinson's disease in Norway. Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476 [TBL] [Abstract][Full Text] [Related]
18. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691 [TBL] [Abstract][Full Text] [Related]
19. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa. Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816 [TBL] [Abstract][Full Text] [Related]
20. [Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson's disease]. Santos-Garcia D; de Deus T; Lopez-Pazos E; Macias-Arribi M; Llaneza-Gonzalez MA; Echarri-Piudo A; Carpintero P; de la Fuente-Fernandez R Rev Neurol; 2014 Jun; 58(11):505-15. PubMed ID: 24861226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]